

P.E.I. Pharmacare Bulletin

Issue (2018-3)

May 14, 2018

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (Effective Date: May 28, 2018)

Product (Generic Name)	Product (Brand Name)	Strength	Dosage Form	DIN	MFR
Escitalopram	<u>Cipralex and various generics</u>	10 mg 20 mg	Tablet Tablet	Various	Various
	Criteria	Open benefit			
	Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Generic Drug Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program			
Fluoxetine	<u>Apo-Fluoxetine</u>	4 mg/1 ml	Oral Solution	02231328	APX
	Criteria	For use in patients for whom oral capsules are not an option			
	Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Generic Drug Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program			
Ixekizumab	<u>Taltz</u>	80 mg/ml 80 mg/ml	Autoinjector Syringe	02455102 02455110	LIL
	Criteria	For the treatment of plaque psoriasis. Please see criteria for plaque psoriasis in the PEI Pharmacare Formulary under Plaque Psoriasis Biologic Agents https://www.princeedwardisland.ca/sites/default/files/publications/pei_pharmacare_formulary.pdf			
	Program Eligibility	High Cost Drug Program, Catastrophic Drug Program			
Levonorgestrel Intrauterine System	<u>Kyleena</u>	19.5 mg	Intrauterine System	02459523	BAY
	Criteria	Open benefit			
	Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Catastrophic Drug Program			
Velaglucerase alfa	<u>VPRIV</u>	400 unit	Vial	02357119	SHR
	Criteria	For patients with Gaucher disease type 1 (GD1) who meet established clinical criteria			
	Program Eligibility	High Cost Drug Program, Catastrophic Drug Program			

IMPORTANT NOTICES

Effective immediately, Minocycline 50 mg and 100 mg capsules (Minocin and various generics) have become open benefits and no longer require Special Authorization.

Effective immediately, Carvedilol 3.125 mg, 6.25 mg, 12.5 mg and 25 mg tablets have become open benefits and no longer require Special Authorization.

Effective immediately, Pramipexole 0.25 mg, 1 mg, and 1.5 mg tablets have become open benefits and no longer require Special Authorization. Pramipexole 0.5 mg tablets will no longer be an eligible benefit under any Pharmacare program.

PEI Pharmacare had previously identified Accel-sevelamer (DIN 02461501) as being added to the PEI Pharmacare Formulary effective March 26, 2018. Due to Health Canada's designation of the product and a re-evaluation of the product at a pan-Canadian public drug program level, PEI Pharmacare will not list DIN 02461501 at this time.